MarketPulse

ERLEADA

2 articles
BenzingaBenzinga··Vandana Singh

J&J Posts Strong Q1 Earnings Beat on Cancer Drug Surge, but Free Cash Flow Tumbles 56%

Johnson & Johnson beat Q1 earnings expectations with 9.9% revenue growth driven by oncology products, but free cash flow plummeted 55.6% year-over-year.
JNJfree cash flowdividend increase
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Castration-Sensitive Prostate Cancer Market to Double to $11.75B by 2036

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.
JNJMRKPFENVSAZN+2Xtandicastration-sensitive prostate cancer